Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Diptee A. Kulkarni"'
Autor:
Keren J. Carss, Aimee M. Deaton, Alberto Del Rio-Espinola, Dorothée Diogo, Mark Fielden, Diptee A. Kulkarni, Jonathan Moggs, Peter Newham, Matthew R. Nelson, Frank D. Sistare, Lucas D. Ward, Jing Yuan
Publikováno v:
Nature Reviews Drug Discovery. 22:145-162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d65a4e33cccbc51f5c412d2c20da9fed
https://doi.org/10.1038/s41573-022-00561-w
https://doi.org/10.1038/s41573-022-00561-w
Autor:
Donald P. Bottaro, Ronnie T.P. Poon, Lone Harild Ottesen, Howard Kallender, Diptee A. Kulkarni, Kristen E. Raffensperger, Yuan Liu, Robert C. Gagnon, Donna S. Cox, Aaron Camp, Theeranun Sanpajit, Pei-Jer Chen, Wirote Lausoontornsiri, Chia-Jui Yen, Yee Chao, Wattana Sukeepaisarnjaroen, Riccardo Lencioni, Thomas C.C. Yau
Association of NR1I3 haplotype with TTP (Supplementary Online only). CAT/CAT carriers, median TTP 1.92 months vs 6.21 months for CAT/â^' or â^'/â^' carriers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd1825e834816ea73536b314c3936e9
https://doi.org/10.1158/1078-0432.22466073.v1
https://doi.org/10.1158/1078-0432.22466073.v1
Autor:
Donald P. Bottaro, Ronnie T.P. Poon, Lone Harild Ottesen, Howard Kallender, Diptee A. Kulkarni, Kristen E. Raffensperger, Yuan Liu, Robert C. Gagnon, Donna S. Cox, Aaron Camp, Theeranun Sanpajit, Pei-Jer Chen, Wirote Lausoontornsiri, Chia-Jui Yen, Yee Chao, Wattana Sukeepaisarnjaroen, Riccardo Lencioni, Thomas C.C. Yau
Purpose: This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd95dc8c9a5274b26a5becd46455754
https://doi.org/10.1158/1078-0432.c.6526233
https://doi.org/10.1158/1078-0432.c.6526233
Autor:
Donald P. Bottaro, Ronnie T.P. Poon, Lone Harild Ottesen, Howard Kallender, Diptee A. Kulkarni, Kristen E. Raffensperger, Yuan Liu, Robert C. Gagnon, Donna S. Cox, Aaron Camp, Theeranun Sanpajit, Pei-Jer Chen, Wirote Lausoontornsiri, Chia-Jui Yen, Yee Chao, Wattana Sukeepaisarnjaroen, Riccardo Lencioni, Thomas C.C. Yau
Table S1: Summary of pharmacokinetic parameters (days 1 and 15); Table S2: Significant changes in circulating biomarkers from baseline; Table S3: Multivariate models for selected covariates, Overall Survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c16b04d0a46f6015be121524d955e0
https://doi.org/10.1158/1078-0432.22466070
https://doi.org/10.1158/1078-0432.22466070
Autor:
Keren J, Carss, Aimee M, Deaton, Alberto, Del Rio-Espinola, Dorothée, Diogo, Mark, Fielden, Diptee A, Kulkarni, Jonathan, Moggs, Peter, Newham, Matthew R, Nelson, Frank D, Sistare, Lucas D, Ward, Jing, Yuan
Publikováno v:
Nature reviews. Drug discovery.
Human genetics research has discovered thousands of proteins associated with complex and rare diseases. Genome-wide association studies (GWAS) and studies of Mendelian disease have resulted in an increased understanding of the role of gene function a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e832c755e4fac47d83b77727d6f224f
https://pubmed.ncbi.nlm.nih.gov/36261593
https://pubmed.ncbi.nlm.nih.gov/36261593
Autor:
Jeff Legos, Bijoyesh Mookerjee, Kijoung Song, Colin F. Spraggs, Diptee A. Kulkarni, Linda Briley, Christine Dabrowski, Karen S. King
Publikováno v:
Pharmacogenomics. 17:459-462
Aim: Pyrexia is a common adverse event (AE) on dabrafenib treatment (monotherapy or combination with trametinib). Since germline SNPs and HLA alleles are implicated in drug-induced AEs, this study investigated their association with pyrexia. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab79cc34c1a58f26d085d9df2c8ff322
https://doi.org/10.2217/pgs.16.4
https://doi.org/10.2217/pgs.16.4
Autor:
Theeranun Sanpajit, Diptee A. Kulkarni, Thomas Yau, Yee Chao, Wattana Sukeepaisarnjaroen, Ronnie T.P. Poon, Yuan Liu, A. Camp, Riccardo Lencioni, Robert C. Gagnon, Pei-Jer Chen, Kristen Raffensperger, Howard Kallender, Donna S. Cox, Wirote Lausoontornsiri, Donald P. Bottaro, Lone Ottesen, Chia Jui Yen
Purpose: This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b72aec41990dec0d9357bcab7e3e151
http://hdl.handle.net/11568/902267
http://hdl.handle.net/11568/902267
Publikováno v:
Cancer Research. 77:1284-1284
Tumorigenesis in sporadic cancers is mainly driven by somatic genetic alterations such as driver mutations in protein coding genes or chromosomal changes comprising deletions, amplifications or translocations resulting in loss of tumor suppressor pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5264df548f2a48ce8a2d02d21c7d79d
https://doi.org/10.1158/1538-7445.am2017-1284
https://doi.org/10.1158/1538-7445.am2017-1284
Autor:
Linda P. Briley, Karen S. King, Diptee A. Kulkarni, Jeffrey J. Legos, C. Dabrowski, Heather Lynn Del Buono, Bijoyesh Mookerjee, Colin F. Spraggs, Kijoung Song
Publikováno v:
Journal of Clinical Oncology. 33:e20026-e20026
e20026 Background: Dabrafenib (D) and trametinib (T) single agents have superior efficacy compared with chemotherapy in metastatic melanoma with BRAF V600E/K mutation, and their use in combination ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::914d40cab75a5039f810d0a29017434e
https://doi.org/10.1200/jco.2015.33.15_suppl.e20026
https://doi.org/10.1200/jco.2015.33.15_suppl.e20026
Autor:
Judong Shen, Linda P. Briley, Suzanne Swann, Karen S. King, Diptee A. Kulkarni, Colin F. Spraggs, Kiran Patel, Gursel Aktan
Publikováno v:
Journal of Clinical Oncology. 32:e20018-e20018
e20018 Background: Dabrafenib (D) is approved for the treatment of BRAF V600E–mutated metastatic melanoma (MM). Multiple resistance mechanisms to D have been reported, but no validated biomarkers e...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a43795cf53350ce053f9bdfdb5d402bf
https://doi.org/10.1200/jco.2014.32.15_suppl.e20018
https://doi.org/10.1200/jco.2014.32.15_suppl.e20018